Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AMEN!!!
Surf oncology paying VCNX for its technology
Guess who has a big stake in Surf?.
non other than Cathie Wood from Ark investment which ran Tsla from $50 to $700 plus
Great endorsement for VCNX
SUNW GOING to $15
See quote from press release
Deal SUBJECT TO SHAREHOLDER APPROVAL vote in 4Q if not cancelled before then
Transaction Details
The transaction is expected to close during the fourth quarter of 2020, subject to approval by shareholders of both companies and other customary closing conditions.
SUNW TO $ 15 per share
PECK deal will be Cancelled Prior to 4Q-
Deal requires SUNW MGMT AND shareholders approval
They will NOT APPROVE
Going to $15 per share
No way this deal goes thru - SUNW shareholders would have to approve it in 4Q- no way it will be approved by SUNW shareholders given the latest news
Forget the crap hedge fund
CODX reported 1.5 million in sales in the first quarter
and 18 million more sales through half of the second quarter with lots more to come If you double it that’s 36 million in the second quarter
consider this a good buying opportunity
Link please chilling
Agree they are still late to the party and once the patent lawsuit is concluded we should be trading about five times higher than the current price
No this was not an error
you might remember that Goldman Sachs had a 7dollar price target probably four/five months ago
Goldman sacks from $7 to $28 is big
and 143% from current prices is big
Ty both
If Closing briefs are due February 28 approximately when do we think the judge will rule?
What do you think the status of the JV is and when do you think they will have some product on the shelves to sell?
https://finviz.com/quote.ashx?t=AMRN
See total short share a percentage 32%
The total short shares are about 45 million
Total outstanding shares are about 350 million
however the Float shares are only 150 million or 32%
As you can see from the short report that short staffed not materially changed from November 30
https://nakedshortreport.com/company/AMRN
One Third of the outstanding float is short which is 45 million shares as of 11/30
Friday night about 3 million shares traded in after hours on Friday hence there are still ~42 million shares are still short and will need to cover
I’m looking for about 29 or 30 pps tomorrow
I Heartily agree Evaporate and Brave will bring new Value to AMRN.
As I understand it Evaporate is an 18 month study that should conclude about July/August 2020 and support reduction of plaque and inflammation in a wider range of illnesses for patients.
I think I have heard that the FDA can allow a study to terminate early if the benefits are great so that it can get in the hands of patients earlier.
I too would like some clarity on this process in the FDA
US diabetic population is 30 million
Pre-diabetics or 70 million
Based on Lipitor/PFE 10 year sales were $100 billion with peak sales at $13 billion. I would say Vascepa would be at least that and probably more with additional supplementals coming for NASH. Etc
What are the three categories represent please?
Transactions
Prescriptions
Normalized trans
Number of patients
Other
One more possibility sell a portion of the business for let’s say USA/ n Amer and keep Europe in a Jt venture thus getting the best of both worlds
For your information prior to generic statins — Lipitor had about $10 billion in annual average sales annually for about 10 years I think the peak annual sales were 13 billion
American heart Association And American diabetes Association have already recognize the importance of Vasecpa for improving health outcomes At a lower cost advantage to boot
This will happen very much prior to generics
Here is a my simple take on the Evaporate study
The Evaporate study showed that plaque was significantly reduce within only nine months (study going for 18 months total)– and had the most reduction for those with the worst situations. This was proven by imaging the arteries. Total plaque was reduced 42% however that was not part of the original target metrics hence the misinformation/confusion.
Also the cost-benefit study was very favorable -it shows that this was Dominant meaning the cost for the new drugs were less than the benefits received (lower cost overall). This is not usually the case is normally there is an increase cost to have some medical improvement. This supports the Reduce It study and also supports the label expansion and hence the future BLOCKBUSTER sales starting this coming year.
——
I believe ADA has Vascepa as part of their SOC – standard care and there are over 30 million diabetics and 70 million prediabetic‘s in the US alone versus only 400,000 patients on Vascepa today.
We should see some movement Today back to the 24/25 range -as yesterday’s drop off is a gift to be taken advantage of. This is a great set up for PDUFA on or before 12/28.
Looking forward to the analysts updating their numbers soon – currently high is 51 ( before the 16-0 vote) average is 33 prior to th e 16-0 vote and Evaporate
Long AMRN
I would think we should see some good price movement this week back to 24 or 25
Evaporate study showed that plaque was significantly reduced within only 9 months ( study going for 18 months)and had the most Reduction for those with the worst situations. this was proven by imaging the arteries. Total plaque was reduced 42% however that was not part of the original target metrics hence the misinformation/confusion
Also the cost benefit study was very favorable – it showed that this was Dominant meaning the cost for the new drugs were less than the benefits received. This is not usually the case as normally there is an additional cost needed to have some medical improvement
Analyst will eventually catch up with their price
targets especially after PDUFA on Or before 12 /28
Long AMRN
Wil Lar
If AMRN does not R&D and manufacturing ( as you say - I do not know) that is actually a BIG PLUS (good thing versus a negative) because big Pharma already has R&D and manufacturing so there’s no need to pay for that as they can use their own.
Consequently, This should enhance the number of companies who are interested in buying AMRN thus creating a lively market place for our suitors
What competition does SRUTF have with water soluble solutions ?
Please confirm is Ad com open to the public?
Upcoming Catalyst
Dang Siri
Last quarter was reported on 7/30/19 look for current quarter ER on or about 10/30/19
Upcoming Catalyst Earnings Release
Last quarter was reported on July 30 his look for airport as early as October 30
They are already doing $64 million per year ( based on annualized 2Q19 $16 million)
$50 a day is $1500 per month per store or $100 million per year
Growth rate 36% y/y as of June 2019 plus increase in retail outlets from about 3400 to 5400 in 3Q19 will lead to much higher growth for the only GRAS CBD company. 3Q 19 reports should be spectacular for this low price stock
20800000.
If you open the article you’ll see that with the voice mode was NOT CBD but a synthetic
Correction
The end of the sentence was not supposed to be a ?
That was supposed to be a smiley face icon
Thanks again
Long SRUTF can’t wait for the next 4/5 weeks to pass
Thanks for your interesting report ??